Dr. Sankhala on Challenges Facing the Treatment of Angiosarcoma

Kumar Sankhala, MD
Published: Tuesday, Jul 18, 2017



Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma as it is a very aggressive tumor, explains Sankhala. There are some chemotherapy drugs such as paclitaxel and doxorubicin that respond very well but recurs and progresses quickly.

According to Sankhala, the discovery of the TRC105 and pazopanib will hopefully achieve prolonged stabilization of the responses in these patients with angiosarcoma, states Sankhala.
 


Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma as it is a very aggressive tumor, explains Sankhala. There are some chemotherapy drugs such as paclitaxel and doxorubicin that respond very well but recurs and progresses quickly.

According to Sankhala, the discovery of the TRC105 and pazopanib will hopefully achieve prolonged stabilization of the responses in these patients with angiosarcoma, states Sankhala.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x